Skip to content
Blerp – Lifestyle
Author:
Sagimet Biosciences Inc.
Sagimet Biosciences to Participate in the Canaccord Genuity 46th Annual Growth Conference
August 4, 2026
Sagimet Biosciences Joins the Russell 2000® and Russell 3000® Indexes
June 29, 2026
Sagimet Biosciences Announces Participation in Upcoming Investor Conference and Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
June 22, 2026
Sagimet Biosciences Presents Two Posters at EASL 2026 on Denifanstat/Resmetirom Combination in MASH
May 27, 2026
Sagimet Biosciences to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ
May 13, 2026
Sagimet Biosciences Reports First Quarter 2026 Financial Results and Provides Corporate Updates
May 12, 2026
Sagimet Biosciences to Present Mechanism of Action Data for its FASN Inhibitors at the Society for Investigative Dermatology in Chicago
May 11, 2026
Sagimet Biosciences Announces Pricing of $175.0 Million Underwritten Offering of Series A Common Stock
April 27, 2026
Sagimet Biosciences Provides Strategic and Corporate Updates
April 27, 2026
Sagimet Biosciences Announces Appointment of Andreas Grauer, MD, as Chief Medical Officer
April 20, 2026
1
2
Next Page
→